Citations (122)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (19)
Mohamed Zakee Mohamed Jiffry, Robert Kloss, Mohammad Ahmed-khan, Felipe Carmona-Pires, Nkechi Okam, Prabasha Weeraddana, Dinusha Dharmaratna, Mehndi Dandwani & Kayvon Moin. (2023) A review of treatment options employed in relapsed/refractory AML. Hematology 28:1.
Read now
Read now
Eric Huselton, Michael P. Rettig, Theresa Fletcher, Julie Ritchey, Leah Gehrs, Kyle McFarland, Stephanie Christ, William C. Eades, Kathryn Trinkaus, Rizwan Romee, Shashikant Kulkarni, Armin Ghobadi, Camille Abboud, Amanda F. Cashen, Keith Stockerl-Goldstein, Geoffrey L. Uy, Ravi Vij, Peter Westervelt, John F. DiPersio & Mark A. Schroeder. (2021) A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes. Leukemia & Lymphoma 62:6, pages 1441-1449.
Read now
Read now
Bhavik J. Pandya, Hongbo Yang, Cynthia Schmeichel, Cynthia Z. Qi & Manasee V. Shah. (2021) A budget impact analysis of gilteritinib for the treatment of relapsed or refractory FLT3mut+ acute myeloid leukemia in a US health plan. Journal of Medical Economics 24:1, pages 19-28.
Read now
Read now
Christopher Arthur, Anthony Jeffrey, Eva Yip, Vicki Katsioulas, Anastasios Nalpantidis, Ian Kerridge, Matthew Greenwood, Luke Coyle, Naomi Mackinlay, Keith Fay, Anoop Enjeti, Jake Shortt & William Stevenson. (2020) Prolonged administration of low-dose cytarabine and thioguanine in elderly patients with acute myeloid leukaemia (AML) achieves high complete remission rates and prolonged survival. Leukemia & Lymphoma 61:4, pages 831-839.
Read now
Read now
Bhavana Bhatnagar, Qiuhong Zhao, Alice S. Mims, Sumithira Vasu, Gregory K. Behbehani, Karilyn Larkin, James S. Blachly, William Blum, Rebecca B. Klisovic, Amy S. Ruppert, Shelley Orwick, Christopher Oakes, Parvathi Ranganathan, John C. Byrd, Alison R. Walker & Ramiro Garzon. (2020) Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study. Leukemia & Lymphoma 61:2, pages 387-396.
Read now
Read now
Liping Dou, Qingyu Xu, Mengzhen Wang, Yang Xiao, Longcan Cheng, Honghua Li, Wenrong Huang, Junhui Mei, Yu Jing, Jian Bo, Daihong Liu & Li Yu. (2019) Clinical efficacy of decitabine in combination with standard-dose cytarabine, aclarubicin hydrochloride, and granulocyte colony-stimulating factor in the treatment of young patients with newly diagnosed acute myeloid leukemia. OncoTargets and Therapy 12, pages 5013-5023.
Read now
Read now
Yuan-yuan Ma, Min Zhao, Yi Liu, De-feng Zhao, Li-xin Wang, Xiao-ping Chen & Li Li. (2019) Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis. Hematology 24:1, pages 507-515.
Read now
Read now
Limin Li, Xiaoqian Zhang, Hongjuan Yu, Mingwen Zhang, Mengyuan Xu, Jie Liu, Yueyue Fu, Hongbin Meng, Chengfang Lyu, Xiaoxia Li & Jin Zhou. (2018) Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations. OncoTargets and Therapy 11, pages 6863-6870.
Read now
Read now
Wei-Yang Li, Ying Wang, Su-Ning Chen, Hui-Ying Qiu, Zheng-Zheng Fu, De-Pei Wu & Ai-Ning Sun. (2018) Consolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission. Leukemia & Lymphoma 59:7, pages 1652-1658.
Read now
Read now
John N. Allan, Gail J. Roboz, Gulce Askin, Ellen Ritchie, Joseph Scandura, Paul Christos, Duane C. Hassane & Monica L. Guzman. (2018) CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine. Leukemia & Lymphoma 59:4, pages 821-828.
Read now
Read now
Jonathan A. Webster & Keith W. Pratz. (2018) Acute myeloid leukemia in the elderly: therapeutic options and choice. Leukemia & Lymphoma 59:2, pages 274-287.
Read now
Read now
Vijaya Raj Bhatt, Krishna Gundabolu, Thuy Koll & Lori J. Maness. (2018) Initial therapy for acute myeloid leukemia in older patients: principles of care. Leukemia & Lymphoma 59:1, pages 29-41.
Read now
Read now
Niloufer Khan, Andrew Hantel, Randall W. Knoebel, Andrew Artz, Richard A. Larson, Lucy A. Godley, Michael J. Thirman, Hongtao Liu, Jane E. Churpek, Darren King, Olatoyosi Odenike & Wendy Stock. (2017) Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leukemia & Lymphoma 58:9, pages 2127-2133.
Read now
Read now
Pasquale Niscola, Benedetta Neri, Gianfranco Catalano, Luciana Morino, Marco Giovannini, Laura Scaramucci, Stefano Fratoni, Nélida Inés Noguera, Iole Cordone & Paolo de Fabritiis. (2017) Decitabine as salvage therapy for primary induction failure of acute myeloid leukemia. Acta Oncologica 56:8, pages 1120-1121.
Read now
Read now
Xing-Nong Ye, Xin-Ping Zhou, Ju-Ying Wei, Gai-Xiang Xu, Ying Li, Li-Ping Mao, Jian Huang, Yan-Ling Ren, Chen Mei, Jing-Han Wang, Yin-Jun Lou, Li-Ya Ma, Wen-Juan Yu, Li Ye, Li-Li Xie, Yin-Wan Luo, Chao Hu, Lin-Mei Niu, Min-Hua Dou, Jie Jin & Hong-Yan Tong. (2016) Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms. Leukemia & Lymphoma 57:6, pages 1311-1318.
Read now
Read now
James Mccloskey, Jamie Koprivnikar & Stefan Faderl. (2015) Sapacitabine in acute myelogenous leukemia. Expert Opinion on Orphan Drugs 3:12, pages 1461-1468.
Read now
Read now
Riad O El Fakih, Richard Champlin & Betul Oran. (2015) RETRACTED ARTICLE: 5-Azacitidine for treating acute myelogenous leukemia. Expert Opinion on Orphan Drugs 3:10, pages 1197-1207.
Read now
Read now
Vu H. Duong, Bhavana Bhatnagar, Dan P. Zandberg, Emily J. Vannorsdall, Michael L. Tidwell, Qing Chen & Maria R. Baer. (2015) Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine. Leukemia & Lymphoma 56:6, pages 1718-1722.
Read now
Read now
Bhavana Bhatnagar, Vu H. Duong, Theodore S. Gourdin, Michael L. Tidwell, Ching Chen, Yi Ning, Ashkan Emadi, Edward A. Sausville & Maria R. Baer. (2014) Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy. Leukemia & Lymphoma 55:7, pages 1533-1537.
Read now
Read now
Articles from other publishers (103)
Yu Fu, Long Su, Yuying Li & Yehui Tan. (2023) Decitabine combined with low-dose cytarabine, aclarubicin and rhG-CSF regimen may be a potential alternative for relapsed/refractory acute myeloid leukemia: A single-center study. memo - Magazine of European Medical Oncology.
Crossref
Crossref
Michael Lübbert, Pierre W Wijermans, Michal Kicinski, Sylvain Chantepie, Walter J F M Van der Velden, Richard Noppeney, Laimonas Griškevičius, Andreas Neubauer, Martina Crysandt, Radovan Vrhovac, Mario Luppi, Stephan Fuhrmann, Ernesta Audisio, Anna Candoni, Olivier Legrand, Robin Foà, Gianluca Gaidano, Danielle van Lammeren-Venema, Eduardus F M Posthuma, Mels Hoogendoorn, Anne Giraut, Marian Stevens-Kroef, Joop H Jansen, Aniek O de Graaf, Fabio Efficace, Emanuele Ammatuna, Jean-Pierre Vilque, Ralph Wäsch, Heiko Becker, Nicole Blijlevens, Ulrich Dührsen, Frédéric Baron, Stefan Suciu, Sergio Amadori, Adriano Venditti, Gerwin Huls, Jürgen Finke, Nicolaas Petrus Michael Schaap, Andrius Zucenka, Stephan Metzelder, Edgar Jost, Zinaida Perić, Fabio Forghieri, Bernadino Allione, Maurizio Martelli, Anna Paola Iori, Sebastian Wittnebel, Andrea Mengarelli, Annalisa Imovilli, Attilio Olivieri, Bernard José Marie De Prijck, Marjolein W.M. van der Poel, Christian Junghanß, Helmut Rainer Salih, Agostino Tafuri, José Eduardo Guimarães, Maurizio Musso, Paolo De Fabritiis, Patrice Chevallier, Dominik Luc Selleslag, Nicola Cascavilla, Zwi Berneman, Aurélie Jaspers, Eliana Zuffa, Gaëtan Vanstraelen, Giuseppe Visani, Maria Louisa Henriëtte Cuijpers, Ann De Becker, Anna Maria Mianulli, Björn Hackanson, Georgi Georgiev Mihaylov, Giovanni Martinelli, Stefania Paolini, Pier Luigi Zinzani, Martin Henkes, Haifa Kathrin Al-Ali, Paul La Rosée, Anna Chierichini, Laura Cudillo, Giorgina Specchia, Njetočka Gredelj Šimec, Silvana Franca Capalbo, Giuseppina Spinosa, Stefano Molica & Susan Dorothé de Jonge-Peeters. (2023) 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial. The Lancet Haematology 10:11, pages e879-e889.
Crossref
Crossref
Maximilian Schmutz, Manuela Zucknick, Richard F. Schlenk, Daniel Mertens, Axel Benner, Dieter Weichenhan, Oliver Mücke, Konstanze Döhner, Christoph Plass, Lars Bullinger & Rainer Claus. (2023) Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen. Clinical Epigenetics 15:1.
Crossref
Crossref
Jacobien R. Hilberink, Isabelle A. van Zeventer, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Peter J. M. Valk, Jacqueline Cloos, Arjan A. van de Loosdrecht, Dimitri Breems, Danielle van Lammeren-Venema, Rinske Boersma, Mojca Jongen-Lavrencic, Martin Fehr, Mels Hoogendoorn, Markus G. Manz, Maaike Söhne, Rien van Marwijk Kooy, Dries Deeren, Marjolein W. M. van der Poel, Marie Cecile Legdeur, Lidwine Tick, Yves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg, Gert J. Ossenkoppele, D. A. Chitu, S. K. Klein, L. Griskevicius, P. J. M. Valk, J. Cloos, A. A. van de Loosdrecht, D. Breems, D. van Lammeren-Venema, R. Boersma, M. Jongen-Lavrencic, M. Söhne, R. van Marwijk Kooy, D. Deeren, M. W. M. van der Poel, M. C. Legdeur, L. Tick, E. Ammatuna, B. Löwenberg, G. J. Ossenkoppele, G. Huls, T. Pabst, G. Stussi, M. Fehr, M. G. Manz, Y. Chalandon, S. Blum & Gerwin Huls. (2023) Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine. Blood Cancer Journal 13:1.
Crossref
Crossref
Hussein Awada, Carmelo Gurnari, Zhuoer Xie, Jan Philipp Bewersdorf & Amer M. Zeidan. (2023) What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach. Cancers 15:8, pages 2248.
Crossref
Crossref
Stéphane de Botton, Pau Montesinos, Andre C. Schuh, Cristina Papayannidis, Paresh Vyas, Andrew H. Wei, Hans Ommen, Sergey Semochkin, Hee-Je Kim, Richard A. Larson, Jaime Koprivnikar, Olga Frankfurt, Felicitas Thol, Jörg Chromik, Jenny Byrne, Arnaud Pigneux, Xavier Thomas, Olga Salamero, Maria Belen Vidriales, Vadim Doronin, Hartmut Döhner, Amir T. Fathi, Eric Laille, Xin Yu, Maroof Hasan, Patricia Martin-Regueira & Courtney D. DiNardo. (2023)
Enasidenib vs conventional care in older patients with late-stage mutant-
IDH2
relapsed/refractory AML: a randomized phase 3 trial
. Blood 141:2, pages 156-167.
Crossref
Crossref
Robert Briski, Guillermo Garcia-Manero, Hagop Kantarjian & Farhad Ravandi. (2023) The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia. Therapeutic Advances in Hematology 14.
Crossref
Crossref
Viviane Regina Hernandez Nunes, Isabella Silva e Pimentel, Mariana Nassif Kerbauy, Carolina Cristina Pellegrino Feres, Jade Zezzi Martins do Nascimento, Andreza Alice Feitosa Ribeiro, Amanda Inacio Dias dos Santos, Marcelo Langer Wroclawski, Larissa Lane Cardoso Teixeira & Nelson Hamerschlak. (2023) Urinary retention after use of decitabine in acute myeloid leukemia: case report. Hematology, Transfusion and Cell Therapy 45:1, pages 110-112.
Crossref
Crossref
Hongchao Yuan, Yuanjun Lu, Yibin Feng & Ning Wang. 2023.
Nicholas J. Short & Hagop Kantarjian. (2022) Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions. American Journal of Hematology 97:12, pages 1616-1626.
Crossref
Crossref
Maria R. BaerAksinija A. KoganSøren M. BentzenTian Mi, Rena G. LapidusVu H. DuongAshkan EmadiSandrine NiyongereCasey L. O'Connell, Benjamin A. YoungbloodStephen B. Baylin & Feyruz V. Rassool. (2022) Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia. Clinical Cancer Research 28:7, pages 1313-1322.
Crossref
Crossref
Michelina Dargenio, Giuseppe Tarantini, Nicola Cascavilla, Enzo Pavone, Pellegrino Musto, Patrizio Mazza, Lorella Melillo, Domenico Pastore, Attilio Guarini, Caterina Buquicchio, Maria Paola Fina, Vincenzo Federico, Teresa Maria Santeramo, Marina Aurora Urbano, Mariangela Leo, Vera Carluccio, Paola Carluccio, Mario Delia, Daniela Carlino, Carolina Vergine, Vito Pier Gagliardi, Giuseppina Greco, Silvia Sibilla, Mariachiara Abbenante, Giovanni Rossi, Giuseppina Spinosa, Annamaria Mazzone, Lara Aprile, Vincenza de Fazio, Crescenza Pasciolla, Giorgina Specchia & Nicola Di Renzo. (2022) Long-Term Follow-Up of Elderly Patients with Acute Myeloid Leukemia Treated with Decitabine: A Real-World Study of the Apulian Hematological Network. Cancers 14:3, pages 826.
Crossref
Crossref
Meghali Goswami, Gege Gui, Laura W Dillon, Katherine E Lindblad, Julie Thompson, Janet Valdez, Dong-Yun Kim, Jack Y Ghannam, Karolyn A Oetjen, Christin B Destefano, Dana M Smith, Hanna Tekleab, Yeusheng Li, Pradeep Dagur, Thomas Hughes, Jennifer L Marté, Jaydira del Rivero, Joanna Klubo-Gwiezdzinksa, James L Gulley, Katherine R Calvo, Catherine Lai & Christopher S Hourigan. (2022) Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia. Journal for ImmunoTherapy of Cancer 10:1, pages e003392.
Crossref
Crossref
Nicholas J. Short, Hervé Dombret, Lionel Adès & Hagop Kantarjian. (2022) The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old Drugs. The Cancer Journal 28:1, pages 29-36.
Crossref
Crossref
Liang Wang, Chun Li, Fang Xu, Fang Cao, Bo Zhang, Jing Wang, Shen Wang, Li Chen, Na Li, Chenglin Liao & Hongjun Liu. (2021) Analysis of efficacy, safety and prognostic factors of DAC‑HAA treatment in Chinese pediatric patients with refractory or relapsed acute myeloid leukemia. Molecular and Clinical Oncology 15:6.
Crossref
Crossref
Eric Huselton, Michael P. Rettig, Kirsten Campbell, Amanda F. Cashen, John F. DiPersio, Feng Gao, Meagan A. Jacoby, Iskra Pusic, Rizwan Romee, Mark A. Schroeder, Geoffrey L. Uy, Stephen Marcus & Peter Westervelt. (2021) Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. Leukemia Research 110, pages 106713.
Crossref
Crossref
Irene Urbino, Carolina Secreto, Matteo Olivi, Vincenzo Apolito, Stefano D’Ardia, Chiara Frairia, Valentina Giai, Semra Aydin, Roberto Freilone, Chiara Dellacasa, Luisa Giaccone, Dario Ferrero, Ernesta Audisio, Alessandro Busca & Marco Cerrano. (2021) Evolving Therapeutic Approaches for Older Patients with Acute Myeloid Leukemia in 2021. Cancers 13:20, pages 5075.
Crossref
Crossref
Raquel Alves, Ana Cristina Gonçalves, Sergio Rutella, António M. Almeida, Javier De Las Rivas, Ioannis P. Trougakos & Ana Bela Sarmento Ribeiro. (2021) Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance. Cancers 13:19, pages 4820.
Crossref
Crossref
Adam S. Zayac & John L. Reagan. (2021) Trials and Tribulations in the Frontline Treatment of Older Adults with Acute Myeloid Leukemia. Hemato 2:3, pages 515-544.
Crossref
Crossref
Federica Lessi, Marica Laurino, Cristina Papayannidis, Orsola Vitagliano, Francesco Grimaldi, Davide Lazzarotto, Michele Gottardi, Elena Crisà, Marta Riva, Gianluigi Reda, Mario Ermani, Gianpietro Semenzato, Livio Trentin & Felicetto Ferrara. (2021) Hypomethylating Agents (HMAs) as Salvage Therapy in Relapsed or Refractory AML: An Italian Multicentric Retrospective Study. Biomedicines 9:8, pages 972.
Crossref
Crossref
Julia Stomper, John Charles Rotondo, Gabriele Greve & Michael Lübbert. (2021) Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia 35:7, pages 1873-1889.
Crossref
Crossref
Justin H. Reid, Bernard L. Marini, Lydia L. Benitez, Kristen Pettit, Dale L. Bixby, Patrick Burke & Anthony J. Perissinotti. (2021) Propensity-score Matched Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 21:6, pages 393-400.e1.
Crossref
Crossref
Douglas D. Fang, Qiuqiong Tang, Yanhui Kong, Tao Rong, Qixin Wang, Na Li, Xu Fang, Jiaxing Gu, Dengkun Xiong, Yan Yin, Jing Deng, Dajun Yang & Yifan Zhai. (2021) MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models. Cell Death Discovery 7:1.
Crossref
Crossref
Ian M. Bouligny, Vivek Mehta, Scott Isom, Leslie R. Ellis, Rupali R. Bhave, Dianna S. Howard, Susan Lyerly, Megan Manuel, Sarah Dralle, Bayard L. Powell & Timothy S. Pardee. (2021) Efficacy of 10-day decitabine in acute myeloid leukemia. Leukemia Research 103, pages 106524.
Crossref
Crossref
Jacobien Hilberink & Gerwin Huls. 2021. Acute Leukemias. Acute Leukemias.
Vassiliki Mpakou, Aris Spathis, Anthi Bouhla, Efthimia Mpazani, Sotirios Papageorgiou, Konstantinos Gkontopoulos, Eirini Glezou, Thomas Thomopoulos, Periklis Foukas & Vasiliki Pappa. (2021) Synergistic inhibitory effects of low‑dose decitabine in combination with bortezomib in the AML cell line Kasumi‑1. Experimental and Therapeutic Medicine 21:3.
Crossref
Crossref
Nadya Jammal, Serena Chew, Farhad Ravandi, Hagop M. Kantarjian & Elias Jabbour. 2021. Acute Leukemias. Acute Leukemias
89
109
.
Lixin Wang, Jianmin Luo, Guofeng Chen, Meiyun Fang, Xudong Wei, Yinghua Li, Zhuogang Liu, Yin Zhang, Sujun Gao, Jianliang Shen, Xin Wang, Xiaoning Gao, Wei Zhou, Yigai Ma, Hui Liu, Xinquan Li, Linhua Yang, Kai Sun & Li Yu. (2020) Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study. Clinical Epigenetics 12:1.
Crossref
Crossref
Wen Yao, Xiandeng CHU, Xinchen Fang, Xiaoyu Zhu, Baolin Tang, Xiang Wan, Liangquan Geng, Juan Tong, Kaidi Song, Xuhan Zhang, Ping Qiang, Guangyu Sun, Huilan Liu & Zimin Sun. (2020) Decitabine prior to salvaged cord blood transplantation for acute myeloid leukaemia/myelodysplastic syndrome not in remission. Journal of Clinical Pharmacy and Therapeutics 45:6, pages 1372-1381.
Crossref
Crossref
Pierre Bories, Naïs Prade, Stéphanie Lagarde, Bastien Cabarrou, Laetitia Largeaud, Julien Plenecassagnes, Isabelle Luquet, Véronique De Mas, Thomas Filleron, Manon Cassou, Audrey Sarry, Luc-Matthieu Fornecker, Célestine Simand, Sarah Bertoli, Christian Recher & Eric Delabesse. (2020) Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine. PLOS ONE 15:10, pages e0238795.
Crossref
Crossref
Courtney D DiNardo, Abhishek Maiti, Caitlin R Rausch, Naveen Pemmaraju, Kiran Naqvi, Naval G Daver, Tapan M Kadia, Gautam Borthakur, Maro Ohanian, Yesid Alvarado, Ghayas C Issa, Guillermo Montalban-Bravo, Nicholas J Short, Musa Yilmaz, Prithviraj Bose, Elias J Jabbour, Koichi Takahashi, Jan A Burger, Guillermo Garcia-Manero, Nitin Jain, Steven M Kornblau, Philip A Thompson, Zeev Estrov, Lucia Masarova, Koji Sasaki, Srdan Verstovsek, Alessandra Ferrajoli, William G Weirda, Sa A Wang, Sergej Konoplev, Zhining Chen, Sherry A Pierce, Jing Ning, Wei Qiao, Farhad Ravandi, Michael Andreeff, John S Welch, Hagop M Kantarjian & Marina Y Konopleva. (2020) 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. The Lancet Haematology 7:10, pages e724-e736.
Crossref
Crossref
Gerwin HulsDana A. ChituThomas PabstSaskia K. KleinGeorg Stussi, Laimonas GriskeviciusPeter J. M. ValkJacqueline Cloos, Arjan A. van de LoosdrechtDimitri BreemsDanielle van Lammeren-VenemaIsabelle van Zeventer, Rinske BoersmaMojca Jongen-LavrencicMartin FehrMels HoogendoornMarkus G. ManzMaaike SöhneRien van Marwijk KooyDries Deeren, Marjolein W. M. van der PoelMarie Cecile LegdeurLidwine TickYves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg & Gert J. Ossenkoppele. (2020) Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS. Blood Advances 4:18, pages 4267-4277.
Crossref
Crossref
Jun H. Choi, James M. Bogenberger & Raoul Tibes. (2020) Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond. Targeted Oncology 15:2, pages 147-162.
Crossref
Crossref
Chenchen Zhao, Bei Jia, Ming Wang, Todd D. Schell, David F. Claxton, W Christopher Ehmann, Witold B. Rybka, Shin Mineishi, Seema Naik, Natthapol Songdej, Jeff M. Sivik, Raymond J. Hohl, Hui Zeng & Hong Zheng. (2019) Multi‐dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML. British Journal of Haematology 188:5, pages 674-684.
Crossref
Crossref
Qingyu Xu, Yan Li, Yu Jing, Na Lv, Lili Wang, Yonghui Li & Li Yu. (2019) Epigenetic modifier gene mutations‐positive AML patients with intermediate‐risk karyotypes benefit from decitabine with CAG regimen. International Journal of Cancer 146:5, pages 1457-1467.
Crossref
Crossref
Maria Assunta Chiacchio, Daniela Iannazzo, Roberto Romeo, Salvatore V. Giofrè & Laura Legnani. (2020) Pyridine and Pyrimidine Derivatives as Privileged Scaffolds in Biologically Active Agents. Current Medicinal Chemistry 26:40, pages 7166-7195.
Crossref
Crossref
Parinaz Mehdipour, Tracy Murphy & Daniel D. De Carvalho. (2020) The role of DNA-demethylating agents in cancer therapy. Pharmacology & Therapeutics 205, pages 107416.
Crossref
Crossref
Mei-Ru Bian, Han-Shi Yang, Guo-Qiang Lin, Yan Wan, Li Wang, Ye-Jun Si, Xin-Xia Zhang, Mao Wang, Hua Zhou, Guang-sheng Zhao & Yan-Ming Zhang. (2019) Decitabine Compared With Conventional Regimens in Older Patients With Acute Myeloid Leukemia: A Meta-Analysis. Clinical Lymphoma Myeloma and Leukemia 19:12, pages e636-e648.
Crossref
Crossref
Monica Bocchia, Anna Candoni, Erika Borlenghi, Marzia Defina, Carla Filì, Chiara Cattaneo, Vincenzo Sammartano, Renato Fanin, Margherita Sciumè, Anna Sicuranza, Silvia Imbergamo, Marta Riva, Nicola Fracchiolla, Roberto Latagliata, Emanuela Caizzi, Francesco Mazziotta, Giulia Alunni, Eros Di Bona, Monica Crugnola, Marianna Rossi, Ugo Consoli, Giulia Fontanelli, Giuseppina Greco, Gianpaolo Nadali, Francesco Rotondo, Elisabetta Todisco, Catia Bigazzi, Enrico Capochiani, Alfredo Molteni, Massimo Bernardi, Monica Fumagalli, Michela Rondoni, Barbara Scappini, Anna Ermacora, Federico Simonetti, Michele Gottardi, Daniela Lambertenghi Deliliers, Mariagrazia Michieli, Claudia Basilico, Carlotta Galeone, Claudio Pelucchi & Giuseppe Rossi. (2019) Real‐world experience with decitabine as a first‐line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy. Hematological Oncology 37:4, pages 447-455.
Crossref
Crossref
Valeria Santini & Gert J. Ossenkoppele. (2019) Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use. Critical Reviews in Oncology/Hematology 140, pages 1-7.
Crossref
Crossref
Joel M Michalski, Elizabeth R Lyden, Andrea J Lee, Zaid S Al-Kadhimi, Lori J Maness, Krishna Gundabolu & Vijaya Raj Bhatt. (2019) Intensity of chemotherapy for the initial management of newly diagnosed acute myeloid leukemia in older patients. Future Oncology 15:17, pages 1989-1995.
Crossref
Crossref
Myrna R. Nahas, Dina Stroopinsky, Jacalyn Rosenblatt, Leandra Cole, Athalia R. Pyzer, Eleni Anastasiadou, Anna Sergeeva, Adam Ephraim, Abigail Washington, Shira Orr, Malgorzata McMasters, Matthew Weinstock, Salvia Jain, Rebecca K. Leaf, Haider Ghiasuddin, Maryam Rahimian, Jessica Liegel, Jeffrey J. Molldrem, Frank Slack, Donald Kufe & David Avigan. (2019) Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine. British Journal of Haematology 185:4, pages 679-690.
Crossref
Crossref
Jacobien Hilberink, Carin Hazenberg, Eva van den Berg, André Mulder, Jan Jacob Schuringa, Lieke van der Helm, Marco de Groot, Goda Choi, Geertruida H. de Bock, Edo Vellenga, Emanuele Ammatuna & Gerwin Huls. (2019) Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: A single center experience of 355 consecutive patients. Leukemia Research 80, pages 33-39.
Crossref
Crossref
Eun-Ji Choi, Je-Hwan Lee, Han-Seung Park, Jung-Hee Lee, Miee Seol, Young-Shin Lee, Young-Ah Kang, Mijin Jeon, Ji Min Woo & Kyoo-Hyung Lee. (2019) Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 19:5, pages 290-299.e3.
Crossref
Crossref
Xuying Pei & Xiaojun Huang. (2019) New approaches in allogenic transplantation in AML. Seminars in Hematology 56:2, pages 147-154.
Crossref
Crossref
Gerwin Huls, Stefan Suciu, Pierre Wijermans, Michal Kicinski & Michael Lübbert. (2019) 10-day vs 5-day decitabine: equivalence cannot be concluded. The Lancet Haematology 6:4, pages e177.
Crossref
Crossref
Alice S. Mims & William Blum. (2019) Progress in the problem of relapsed or refractory acute myeloid leukemia. Current Opinion in Hematology 26:2, pages 88-95.
Crossref
Crossref
Marco Cerrano & Raphael Itzykson. (2019) New Treatment Options for Acute Myeloid Leukemia in 2019. Current Oncology Reports 21:2.
Crossref
Crossref
Carla Filì, Anna Candoni, Maria Elena Zannier, Jacopo Olivieri, Silvia Imbergamo, Manuela Caizzi, Gianpaolo Nadali, Eros Di Bona, Anna Ermacora, Michele Gottardi, Davide Facchinelli, Rosanna Ciancia, Davide Lazzarotto, Maria Vittoria Dubbini, Gianluca Festini, Filippo Gherlinzoni, Maria Grazia Michieli, Gianpietro Semenzato & Renato Fanin. (2019) Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience. Leukemia Research 76, pages 33-38.
Crossref
Crossref
Nicholas J Short, Hagop M Kantarjian, Sanam Loghavi, Xuelin Huang, Wei Qiao, Gautam Borthakur, Tapan M Kadia, Naval Daver, Maro Ohanian, Courtney D Dinardo, Zeev Estrov, Rashmi Kanagal-Shamanna, Abhishek Maiti, Christopher B Benton, Prithviraj Bose, Yesid Alvarado, Elias Jabbour, Steven M Kornblau, Naveen Pemmaraju, Nitin Jain, Yvonne Gasior, Mary Ann Richie, Sherry Pierce, Jorge Cortes, Marina Konopleva, Guillermo Garcia-Manero & Farhad Ravandi. (2019) Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. The Lancet Haematology 6:1, pages e29-e37.
Crossref
Crossref
Gail J. RobozSumithra J. MandrekarPinkal DesaiKristina LaumannAlison R. WalkerEunice S. WangJonathan E. KolitzBayard L. PowellEyal C. AttarWendy StockClara D. BloomfieldJessica KohlschmidtKrzysztof MrózekDuane C. HassaneLevi GarrawayJudit Jané-ValbuenaMichele Baltay, Adam TracyGuido Marcucci, Richard M. StoneRichard A. Larson. (2018) Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Advances 2:24, pages 3608-3617.
Crossref
Crossref
Matthew Mei, Ibrahim Aldoss, Guido Marcucci & Vinod Pullarkat. (2018) Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use. American Journal of Hematology.
Crossref
Crossref
John S. Welch. (2018) Patterns of mutations in TP53 mutated AML. Best Practice & Research Clinical Haematology 31:4, pages 379-383.
Crossref
Crossref
Usama Gergis, Emeline Masson Frenet, Tsiporah Shore, Sebastian Mayer, Adrienne Phillips, Jing-Mei Hsu, Gail Roboz, Ellen Ritchie, Joseph Scandura, Sangmin Lee, Pinkal Desai, Michael Samuel, Jeffrey Ball, Anthony Blanco, Cynthia Romeo, Maria S Albano, Ludy Dobrila, Andromachi Scaradavou & Koen van Besien. (2018) Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes. Biology of Blood and Marrow Transplantation.
Crossref
Crossref
Lili AslostovarAllison L. Boyd, Mohammed AlmakadiTony J. Collins, Darryl P. LeongRommel G. TironaRichard B. KimJim A. JulianAnargyros Xenocostas, Brian Leber, Mark N. LevineRonan FoleyMickie Bhatia. (2018) A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. Blood Advances 2:15, pages 1935-1945.
Crossref
Crossref
Juan Eduardo Megías-Vericat, David Martínez-Cuadrón, Miguel Ángel Sanz & Pau Montesinos. (2018) Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review. Annals of Hematology 97:7, pages 1115-1153.
Crossref
Crossref
Andrew KuykendallNicolas DuployezNicolas BoisselJeffrey E. LancetJohn S. Welch. (2018) Acute Myeloid Leukemia: The Good, the Bad, and the Ugly. American Society of Clinical Oncology Educational Book:38, pages 555-573.
Crossref
Crossref
Maximilian StahlMichelle DeVeauxPau MontesinosRaphael ItzyksonEllen K. RitchieMikkael A. SekeresJohn D. BarnardNikolai A. PodoltsevAndrew M. BrunnerRami S. KomrokjiVijaya R. BhattAref Al-KaliThomas CluzeauValeria SantiniAmir T. FathiGail J. RobozPierre FenauxMark R. LitzowSarah PerreaultTae Kon KimThomas PrebetNorbert VeyVivek VermaUlrich GermingJuan Miguel Bergua, Josefina Serrano, Steven D. GoreAmer M. Zeidan. (2018) Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood Advances 2:8, pages 923-932.
Crossref
Crossref
Armin Rashidi, Daniel J. Weisdorf & Nelli Bejanyan. (2018) Treatment of relapsed/refractory acute myeloid leukaemia in adults. British Journal of Haematology 181:1, pages 27-37.
Crossref
Crossref
Riad El Fakih, Rami Komrokji, Marwan Shaheen, Fahad Almohareb, Walid Rasheed & Mona Hassanein. (2018) Azacitidine Use for Myeloid Neoplasms. Clinical Lymphoma Myeloma and Leukemia 18:4, pages e147-e155.
Crossref
Crossref
Gail J. Roboz, Hagop M. Kantarjian, Karen W. L. Yee, Patricia L. Kropf, Casey L. O'Connell, Elizabeth A. Griffiths, Wendy Stock, Naval G. Daver, Elias Jabbour, Ellen K. Ritchie, Katherine J. Walsh, David Rizzieri, Scott D. Lunin, Tania Curio, Woonbok Chung, Yong Hao, James N. Lowder, Mohammad Azab & Jean-Pierre J. Issa. (2018) Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer 124:2, pages 325-334.
Crossref
Crossref
Jeannette CanyMieke W. H. Roeven, Janneke S. Hoogstad-van Evert, Willemijn HoboFrans MaasRosalia Franco FernandezNicole M. A. Blijlevens, Walter J. van der Velden, Gerwin Huls, Joop H. JansenNicolaas P. M. Schaap & Harry Dolstra. (2018) Decitabine enhances targeting of AML cells by CD34+ progenitor-derived NK cells in NOD/SCID/IL2Rgnull mice. Blood 131:2, pages 202-214.
Crossref
Crossref
Manisha Pant & Vijaya Raj Bhatt. (2017) Early mortality and survival in older adults with acute myeloid leukemia. International Journal of Hematologic Oncology 6:3, pages 61-63.
Crossref
Crossref
Hagop M Kantarjian, Gail J Roboz, Patricia L Kropf, Karen W L Yee, Casey L O'Connell, Raoul Tibes, Katherine J Walsh, Nikolai A Podoltsev, Elizabeth A Griffiths, Elias Jabbour, Guillermo Garcia-Manero, David Rizzieri, Wendy Stock, Michael R Savona, Todd L Rosenblat, Jesus G Berdeja, Farhad Ravandi, Edwin P Rock, Yong Hao, Mohammad Azab & Jean-Pierre J Issa. (2017) Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. The Lancet Oncology 18:10, pages 1317-1326.
Crossref
Crossref
Lieke H. van der Helm, Gerbrig Berger, Arjan Diepstra, Gerwin Huls & Edo Vellenga. (2017) Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia. British Journal of Haematology 178:5, pages 810-812.
Crossref
Crossref
Pere Llinàs-Arias & Manel Esteller. (2017) Epigenetic inactivation of tumour suppressor coding and non-coding genes in human cancer: an update. Open Biology 7:9, pages 170152.
Crossref
Crossref
S. Azizidoost, V. Vijay, C. R. Cogle, E. Khodadi & N. Saki. (2017) The role and clinical implications of the endosteal niche and osteoblasts in regulating leukemia. Clinical and Translational Oncology 19:9, pages 1059-1066.
Crossref
Crossref
Rama Nanah, Kristen McCullough, William Hogan, Kebede Begna, Mrinal Patnaik, Michelle Elliott, Mark Litzow & Aref Al-Kali. (2017) Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience*. American Journal of Hematology 92:9, pages 866-871.
Crossref
Crossref
Peter Tan, Ing Soo Tiong, Shaun Fleming, Giovanna Pomilio, Nik Cummings, Mark Droogleever, Julie McManus, Anthony Schwarer, John Catalano, Sushrut Patil, Sharon Avery, Andrew Spencer & Andrew Wei. (2016) The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study. Oncotarget 8:32, pages 52269-52280.
Crossref
Crossref
Harry Dolstra, Mieke W.H. Roeven, Jan Spanholtz, Basav N. Hangalapura, Marleen Tordoir, Frans Maas, Marij Leenders, Fenna Bohme, Nina Kok, Carel Trilsbeek, Jos Paardekooper, Anniek B. van der Waart, Peter E. Westerweel, Tjeerd J.F. Snijders, Jan Cornelissen, Gerard Bos, Hans F.M. Pruijt, Aniek O. de Graaf, Bert A. van der Reijden, Joop H. Jansen, Arnold van der Meer, Gerwin Huls, Jeannette Cany, Frank Preijers, Nicole M.A. Blijlevens & Nicolaas M. Schaap. (2017) Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients. Clinical Cancer Research 23:15, pages 4107-4118.
Crossref
Crossref
Christoph R?llig, Christian Thiede & Gerhard Ehninger. (2017) Akute myeloische Leuk?mieAcute myeloid leukemia. Der Onkologe 23:7, pages 512-521.
Crossref
Crossref
Pin-Fang He, Jing-Dong Zhou, Dong-Ming Yao, Ji-Chun Ma, Xiang-Mei Wen, Zhi-Hui Zhang, Xin-Yue Lian, Zi-Jun Xu, Jun Qian & Jiang Lin. (2017) Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis. Oncotarget 8:25, pages 41498-41507.
Crossref
Crossref
Lucia Silla, Frederico Dulley, Rosaura Saboya, Fabio Kerbauy, Adriano de Moraes Arantes, Annelise Pezzi, Luisa Grave Gross, Eduardo Paton & Nelson Hamerschlak. (2017) Brazilian guidelines on hematopoietic stem cell transplantation in acute myeloid leukemia. European Journal of Haematology 98:2, pages 177-183.
Crossref
Crossref
Hartmut DöhnerElihu EsteyDavid GrimwadeSergio AmadoriFrederick R. AppelbaumThomas BüchnerHervé DombretBenjamin L. EbertPierre FenauxRichard A. LarsonRoss L. LevineFrancesco Lo-CocoTomoki NaoeDietger NiederwieserGert J. OssenkoppeleMiguel SanzJorge SierraMartin S. TallmanHwei-Fang TienAndrew H. WeiBob Löwenberg & Clara D. Bloomfield. (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:4, pages 424-447.
Crossref
Crossref
Hongyu Zhao, Li Xu, Yongjian Yang, Jianhua Shao, Ping Chen, Xuebin Dong, Linping Gu & Daqi Li. (2017) Successful Management of Decitabine prior to Full-Dose Idarubicin and Cytarabine in the Treatment of Refractory/Recurrent Acute Myeloid Leukemia. Acta Haematologica 137:4, pages 195-200.
Crossref
Crossref
John S. Welch, Allegra A. Petti, Christopher A. Miller, Catrina C. Fronick, Michelle O?Laughlin, Robert S. Fulton, Richard K. Wilson, Jack D. Baty, Eric J. Duncavage, Bevan Tandon, Yi-Shan Lee, Lukas D. Wartman, Geoffrey L. Uy, Armin Ghobadi, Michael H. Tomasson, Iskra Pusic, Rizwan Romee, Todd A. Fehniger, Keith E. Stockerl-Goldstein, Ravi Vij, Stephen T. Oh, Camille N. Abboud, Amanda F. Cashen, Mark A. Schroeder, Meagan A. Jacoby, Sharon E. Heath, Kierstin Luber, Megan R. Janke, Andrew Hantel, Niloufer Khan, Madina J. Sukhanova, Randall W. Knoebel, Wendy Stock, Timothy A. Graubert, Matthew J. Walter, Peter Westervelt, Daniel C. Link, John F. DiPersio & Timothy J. Ley. (2016)
TP53
and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
. New England Journal of Medicine 375:21, pages 2023-2036.
Crossref
Crossref
Miguel A. Sanz, Gloria Iacoboni, Pau Montesinos & Adriano Venditti. (2016) Emerging strategies for the treatment of older patients with acute myeloid leukemia. Annals of Hematology 95:10, pages 1583-1593.
Crossref
Crossref
Jonathan Kell. (2016) Considerations and challenges for patients with refractory and relapsed acute myeloid leukaemia. Leukemia Research 47, pages 149-160.
Crossref
Crossref
Jing Liang, Fan Yang, Liang Zhao, Chongwei Bi & Benzhi Cai. (2016) Physiological and pathological implications of 5-hydroxymethylcytosine in diseases. Oncotarget 7:30, pages 48813-48831.
Crossref
Crossref
Gaurav Goyal, Krishna Gundabolu, Saraschandra Vallabhajosyula, Peter T. Silberstein & Vijaya Raj Bhatt. (2016) Reduced-intensity conditioning allogeneic hematopoietic-cell transplantation for older patients with acute myeloid leukemia. Therapeutic Advances in Hematology 7:3, pages 131-141.
Crossref
Crossref
Marjan Cruijsen, Willemijn Hobo, Walter J.F.M. van der Velden, Manita E.J. Bremmers, Rob Woestenenk, Brigitte Bär, J.H. Frederik Falkenburg, Michel Kester, Nicolaas P.M. Schaap, Joop Jansen, Nicole N.M. Blijlevens, Harry Dolstra & Gerwin Huls. (2016) Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses. Biology of Blood and Marrow Transplantation 22:6, pages 1000-1008.
Crossref
Crossref
Raya Mawad, Pamela S. Becker, Paul Hendrie, Bart Scott, Brent L. Wood, Carol Dean, Vicky Sandhu, Hans Joachim Deeg, Roland Walter, Lixia Wang, Han Myint, Jack W. Singer, Elihu Estey & John M. Pagel. (2016) Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS. British Journal of Haematology 172:2, pages 238-245.
Crossref
Crossref
Xuejie Jiang, Zhixiang Wang, Bingjie Ding, Changxin Yin, Qingxiu Zhong, Bing Z. Carter, Guopan Yu, Ling Jiang, Jieyu Ye, Min Dai, Yu Zhang, Shuang Liang, Qingxia Zhao, Qifa Liu & Fanyi Meng. (2015) The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients. Oncotarget 6:32, pages 33612-33622.
Crossref
Crossref
Jeffrey C. Bryan & Elias J. Jabbour. (2015) Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments. Drugs & Aging 32:8, pages 623-637.
Crossref
Crossref
Tapan M. Kadia, Stefan Faderl, Farhad Ravandi, Elias Jabbour, Guillermo Garcia-Manero, Gautam Borthakur, Alessandra Ferrajoli, Marina Konopleva, Jan Burger, Xuelin Huang, Xuemei Wang, Sherry Pierce, Mark Brandt, Jennie Feliu, Jorge Cortes & Hagop Kantarjian. (2015) Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer 121:14, pages 2375-2382.
Crossref
Crossref
Tapan M. Kadia, Xavier G. Thomas, Anna Dmoszynska, Agnieszka Wierzbowska, Mark Minden, Christopher Arthur, Jacques Delaunay, Farhad Ravandi & Hagop Kantarjian. (2015) Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts. American Journal of Hematology 90:7.
Crossref
Crossref
Neha Gupta, Austin Miller, Shipra Gandhi, Laurie A. Ford, Carlos E. Vigil, Elizabeth A. Griffiths, James E. Thompson, Meir Wetzler & Eunice S. Wang. (2015) Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old. American Journal of Hematology 90:7, pages 639-646.
Crossref
Crossref
Nestor Ramos, Clifton Mo, Judith Karp & Christopher Hourigan. (2015) Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia. Journal of Clinical Medicine 4:4, pages 665-695.
Crossref
Crossref
Tapan M. Kadia, Farhad Ravandi, Susan O'Brien, Jorge Cortes & Hagop M. Kantarjian. (2015) Progress in Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 15:3, pages 139-151.
Crossref
Crossref
Raphael Itzykson, Sylvain Thépot, Céline Berthon, Jacques Delaunay, Didier Bouscary, Thomas Cluzeau, Pascal Turlure, Thomas Prébet, Caroline Dartigeas, Jean-Pierre Marolleau, Christian Recher, Isabelle Plantier, Aspasia Stamatoullas, Alain Devidas, Anne-Laure Taksin, Romain Guièze, Denis Caillot, Norbert Vey, Lionel Adès, Norbert Ifrah, Hervé Dombret, Pierre Fenaux & Claude Gardin. (2015) Azacitidine for the treatment of relapsed and refractory AML in older patients. Leukemia Research 39:2, pages 124-130.
Crossref
Crossref
Ali J Mahdi, Eamon J Mahdi & Steven Knapper. (2015) Chemotherapeutic treatment of acute myeloid leukemia: incorporating the results of recent clinical trials. Clinical Investigation 5:1, pages 89-110.
Crossref
Crossref
Sofie Peirs, Joni Van der Meulen, Inge Van de Walle, Tom Taghon, Frank Speleman, Bruce Poppe & Pieter Van Vlierberghe. (2015) Epigenetics in T-cell acute lymphoblastic leukemia. Immunological Reviews 263:1, pages 50-67.
Crossref
Crossref
Marjan Cruijsen, Michael Lübbert, Pierre Wijermans & Gerwin Huls. (2014) Clinical Results of Hypomethylating Agents in AML Treatment. Journal of Clinical Medicine 4:1, pages 1-17.
Crossref
Crossref
Gail J. Roboz. (2014) Epigenetic targeting and personalized approaches for AML. Hematology 2014:1, pages 44-51.
Crossref
Crossref
Eunice S. Wang. (2014) Treating acute myeloid leukemia in older adults. Hematology 2014:1, pages 14-20.
Crossref
Crossref
Vijaya Raj Bhatt. (2014) Leukemic transformation in essential thrombocythemia. Future Oncology 10:16, pages 2593-2602.
Crossref
Crossref
Sergio Amadori, Maria Ilaria Del Principe & Adriano Venditti. (2014) Advances in the treatment of elderly and frail patients with acute myeloid leukemia. Current Opinion in Oncology 26:6, pages 663-669.
Crossref
Crossref
Gail J. RobozTodd RosenblatMartha ArellanoMarco GobbiJessica K. AltmanPau MontesinosCasey O'ConnellScott R. SolomonArnaud PigneuxNorbert VeyRobert HillsTove Flem JacobsenAthos Gianella-BorradoriØivind FossSylvia VetrhusandFrancis J. Giles. (2014) International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology 32:18, pages 1919-1926.
Crossref
Crossref
Jennifer Davila, Emily Slotkin & Thomas Renaud. (2013) Relapsed and Refractory Pediatric Acute Myeloid Leukemia: Current and Emerging Treatments. Pediatric Drugs 16:2, pages 151-168.
Crossref
Crossref
Monica L. Guzman & John N. Allan. (2014) Concise Review: Leukemia Stem Cells in Personalized Medicine. Stem Cells 32:4, pages 844-851.
Crossref
Crossref
E H Estey. (2013) Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Leukemia 27:9, pages 1803-1812.
Crossref
Crossref
Richard L. Momparler, Sylvie Côté & Louise F. Momparler. (2013) Epigenetic action of decitabine (5-aza-2′-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C). Leukemia Research 37:8, pages 980-984.
Crossref
Crossref
Monique P. Curran. (2013) Decitabine: A Review of its Use in Older Patients with Acute Myeloid Leukaemia. Drugs & Aging 30:6, pages 447-458.
Crossref
Crossref